Fundraising Fox
Cybrexa, Inc.
New Haven, US · Founded 2018 · 2 known investors
Find your way into Cybrexa, Inc.
447 people in our graph can introduce you to the Cybrexa, Inc. team.
Sign up to see every warm intro you have to Cybrexa, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cybrexa, Inc. team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.
Founders & leadership
Cybrexa, Inc. was founded in 2018 by Per Hellsund, Ranjit Bindra, and Peter Glazer.
PH
Per HellsundCo-founder, President & CEOPer Hellsund founded and served as CEO of CyVek Inc. from 2008 to 2014, developing a microfluidic assay platform for life sciences and clinical diagnostics before the company was acquired by Bio-Techne for $105 million; prior to that, he was President of inc.jet Inc., an industrial thermal inkjet technology company, and holds undergraduate degrees in mechanical engineering and business as well as a master's degree in management from Rensselaer Polytechnic Institute.
RB
Ranjit BindraScientific Co-founder & Chief Scientific AdvisorRanjit Bindra is a physician-scientist at the Yale School of Medicine where he directs the Yale Brain Tumor Center and leads an R01-funded research program on synthetic lethal screening strategies in cancer. He has co-founded multiple biotech companies including Cybrexa Therapeutics, Alphina Therapeutics, Modifi Bio (which was acquired by Merck in 2024), and B3 Therapeutics.
FK
F. Kevin DiddenManager
Board
KR
Kevin RakinManager
Investors · 2
Reported raises · per SEC filings
Form D private placements$42.4M disclosed across 3 rounds · 2018–2020
▶$40.2MraisedJun 2022 · 20 investors · OtherRule 506(b)
▶$40.2MraisedJun 2022 · 20 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Per HellsundExecutive Officer, Director
- Michael GrilloDirector
- F. Kevin DiddenDirector
- John HoustonDirector
- Kevin L. RakinDirector
- Offering amount
- $53.7M
- Amount sold
- $40.2M
- Sales commissions
- $75K
- Placement agents
- BFC Group Ltd.
- First sale
- Dec 2020
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$1.7MraisedJan 2020 · 1 investors · OtherRule 506(b)
▶$1.7MraisedJan 2020 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Kevin RakinDirector
- Per HellsundExecutive Officer, Director
- John HoustonDirector
- F. Kevin DiddenDirector
- Offering amount
- $10M
- Amount sold
- $1.7M
- First sale
- Jan 2020
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$500KraisedSep 2018 · 1 investors · OtherRule 506(b)
▶$500KraisedSep 2018 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Kevin RakinDirector
- Per HellsundExecutive Officer, Director
- F. Kevin DiddenDirector
- Offering amount
- $10M
- Amount sold
- $500K
- First sale
- Sep 2018
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Cybrexa, Inc. went on to found or lead other companies.
Related companies · 3
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies working in the same space as Cybrexa, Inc..
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Cybrexa, Inc. do?
- Cybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.
- Who founded Cybrexa, Inc.?
- Cybrexa, Inc. was founded by Per Hellsund, Ranjit Bindra, Peter Glazer in 2018.
- Who are Cybrexa, Inc.'s investors?
- Cybrexa, Inc.'s investors include Connecticut Innovations, HighCape Capital.
- How much funding has Cybrexa, Inc. raised?
- Cybrexa, Inc. has disclosed $42.4M raised across 3 rounds.
- Where is Cybrexa, Inc. headquartered?
- Cybrexa, Inc. is headquartered in New Haven, US.